Aft Pharmaceuticals Ltd. · NZX:AFT
Aft Pharmaceuticals — Shareholder Meeting (August 2025)
30 slides from Aft Pharmaceuticals's shareholder meeting presentation, Aug 1, 2025
Slide 1: 2025 Annual Shareholders' Meeting
For personal use only 2025 ANNUAL SHAREHOLDERS’ MEETING 1 AUGUST 2025
Slide 2: Important Notice
Important Notice For personal use only This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of the performance of AFT. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. This presenta
Slide 3: Welcome
Welcome For personal use only David Flacks Chairman AFT PHARMACEUTICALS WORKING TO IMPROVE YOUR HEALTH 3
Slide 4: Directors
Directors For personal use only Dr Hartley Atkinson Allison Yorston Andrew Lane Managing Director, Chief Independent Director Independent Director Executive Officer Dr Ted Witek Marree Atkinson Independent Director Executive Director, Chief of Staff AFT PHARMACEUTICALS WORKING TO IMPROVE YOUR HEALTH
Slide 5: Agenda
Agenda • Chair address For personal use only • Managing Director’s address • Discussion • Resolutions • General business • Meeting close
Slide 6: Building the Foundation for the Next Phase of Growth
Building the Foundation for the Next Phase of Growth Fortifying AFT’s Global Network to Address Un-met Need CONTINUED STRENGTH IN EXPANDING GLOBAL FOOTPRINT For personal use only ESTABLISHED ANZ BUSINESS • Europe: UK & EU • FY 25 Total Sales $208.0M (5yr CAGR 14%) • North America: USA & Canada • ANZ
Slide 7: Inflection Yields a Balance of Growth and Attractive Shareholder Return
Inflection Yields a Balance of Growth and Attractive Shareholder Return • AFT continues to invest in its product pipeline and commercialization to fuel future commercial market traction and overall growth • Despite continued investment, shareholder equity has grown steadily since FY19 For personal u
Slide 8: Governance and Sustainability
GOVERNANCE AND SUSTAINABILITY DR DOUG WILSON 1937 - 2025 For personal use only Photo: NZME • Allison Yorston joined the Board, bringing than 20 years of blue-chip fast-moving consumer • Former AFT Independent Non-Executive goods, telecommunications and retail marketing experience Director (2012 - 20
Slide 9: Welcome
Welcome For personal use only Dr Hartley Atkinson Managing Director and Chief Executive Officer AFT PHARMACEUTICALS WORKING TO IMPROVE YOUR HEALTH 9
Slide 10: Strategic Efforts Continue to Drive Underlying Momentum
Strategic Efforts Continue to Drive Underlying Momentum KEY HIGHLIGHTS • FY26 revenues reach a new record of $208.0 million up 6% over FY 24 following the neutralisation of 1H 25 disruption • Double digit growth of product sales and royalty income of $207.4; despite lower license income ($0.7 millio
Slide 11: Strong Growth in Australasia Offset by Korean Disruptions
Strong Growth in Australasia Offset by Korean Disruptions AUSTRALIA REVENUE ASIA REVENUE $12.0 For personal use only $127.1 $10.7 $11.1 $120.0 $108.2 $10.0 $100.0 $94.1 $76.7 $76.3 $8.0 $6.8 $5.3 $6.7 $80.0 $68.3 $65.5 $5.5 NZ$M NZ$M $6.0 $60.0 $4.4 $40.0 $4.0 $50.8 $5.4 $20.0 $42.7 $2.0 $4.4 $- $-
Slide 12: AFT's Global Reach
For personal use only AFT’s Global Reach Our medicines are now available in nearly 80 countries around the world AFT PHARMACEUTICALS WORKING TO IMPROVE YOUR HEALTH 12
Slide 13: International Expansion – Investing for Long Term Growth in New Markets
International Expansion – Investing for Long Term Growth in New Markets INTERNATIONAL REVENUE COUNTRIES WHERE MAXIGESIC IS SOLD AND ORDERED $30.0 $27.8 90 For personal use only 80 $25.0 80 73 70 $20.0 61 $16.0 60 COUNTRIES NZ$M $15.0 $13.1 50 46 $11.7 43 $9.9 40 $10.0 19.3 28 15.4 30 10.8 20 $5.0 20
Slide 14: Progressing Expansion of AFT's Global Footprint
Progressing Expansion of AFT’s Global Footprint New markets for our proprietary IP and in-licensed new products are approaching breakeven AFT PHARM USA • Selected OTC launches and coordinate licensees and distributors For personal use only • Work more closely with Hikma • Restructured Combogesic IV
Slide 15: Progressing Expansion of AFT's Global Footprint
Progressing Expansion of AFT’s Global Footprint New markets for our proprietary IP and in-licensed new products are approaching breakeven For personal use only AFT PHARM SOUTH AFRICA (70% AFT) • Purchased an existing company with a SAHPRA license (saves 2 years) • Hired CEO experienced in the hospit
Slide 16: Progressing Research and Development Investments
Progressing Research and Development Investments Several programs have exited development and are moving to revenue generation COMMERCIALISATION EFFORTS For personal use only A significant number of licensing agreement discussions underway RESEARCH AND DEVELOPMENT EXPENSES Maxigesic Multiple Dose Fo
Slide 17: A Strong Research and Development Pipeline
A Strong Research and Development Pipeline AFT’s positive cashflows have positioned the company well to undertake and secure research and development projects either alone or in partnership with others. Project Patents Partners Dossier filing Comment 24 Hospital Injectables Nil Sinoject - AFT 70% 3Q
Slide 18: Outlook: Positioned to Drive Future Growth in Both Revenue and Earnings
Outlook: Positioned to Drive Future Growth in Both Revenue and Earnings • AFT is expecting to extend its growth record in FY 26 and is well positioned to achieve its For personal use only revenue target of $300 million by the end of FY 27. • Operations scaled and benefitted from the expanding geogra
Slide 19: Questions
For personal use only QUESTIONS
Slide 20: Resolutions
For personal use only RESOLUTIONS
Slide 21: Resolution 1: Auditors Remuneration
RESOLUTION 1: AUDITORS REMUNERATION For personal use only That the directors are authorised to fix the fees and expenses of Deloitte as auditor for the 2026 financial year. AFT PHARMACEUTICALS WORKING TO IMPROVE YOUR HEALTH 21
Slide 22: Resolution 2: Re-election of Hartley Atkinson
RESOLUTION 2: RE-ELECTION OF HARTLEY ATKINSON For personal use only That Hartley Atkinson be re-elected as a director of AFT Pharmaceuticals Limited. AFT PHARMACEUTICALS WORKING TO IMPROVE YOUR HEALTH 22
Slide 23: Resolution 3: Election of Allison Yorston
RESOLUTION 3: ELECTION OF ALLISON YORSTON For personal use only That Allison Yorston be elected as a director of AFT Pharmaceuticals Limited. AFT PHARMACEUTICALS WORKING TO IMPROVE YOUR HEALTH 23
Slide 24: Voting and General Business
For personal use only VOTING AND GENERAL BUSINESS
Slide 25: Meeting Close
For personal use only MEETING CLOSE
Slide 26: Appendix 1: History of AFT Pharmaceuticals
Appendix 1: History of AFT Pharmaceuticals For personal use only AFT was founded over 25 years ago by Dr Hartley and Marree Atkinson. Since then, AFT has remained an Atkinson-family controlled business and has grown organically into Australia and internationally The 2015 IPO raised funds to pursue a
Slide 27: Appendix 2: Australasian Product Portfolio
Appendix 2: Australasian Product Portfolio AFT has the #1 selling product (Maxigesic) in the Australian para-ibu1 combo pain relief. AFT’s portfolio includes a combination of over 150 proprietary, branded and generic products which address the following therapeutic areas: For personal use only Pain
Slide 28: Appendix 3: AFT Global Product Portfolio
Appendix 3: AFT Global Product Portfolio AFT is building the global presence of its proprietary and patented products through its network of licensees and distributors. For personal use only It continues the development of its portfolio of repurposed medicines: Maxigesic1, Pascomer, NasoSURF, and Cr
Slide 29: Appendix 4: Reconciliation of EBITDA to GAAP
Appendix 4: Reconciliation of EBITDA to GAAP AFTs standard profit measure prepared under New Zealand GAAP is net profit after tax. AFT has used the non-GAAP profit measure of EBITDA when discussing financial performance in this document. AFT directors and management believe that this measure provide
Slide 30: For More Information
For personal use only FOR MORE INFORMATION Dr Hartley Atkinson Managing Director Email: [email protected] Malcolm Tubby Chief Financial Officer Email: [email protected] AFT Pharmaceuticals Limited Level 1, 129 Hurstmere Road Takapuna, Auckland 0622 New Zealand www.aftpharm.com
AFT Pharmaceuticals — Shareholder Meeting (August 2025) on 6ix